Immuno-Biological Laboratories Co., Ltd. (4570) AI Stock Analysis

• Market Cap: ¥4.87B
• Dividend Yield: N/A
• Average Volume (3M): 98.14K
• Price to Earnings (P/E): 19.6
• Beta (1Y): 0.67
• Revenue Growth: 18.71%
• EPS Growth: 33.40%
• Country: JP
• Employees: 57
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): 12.42
• Shares Outstanding: 9,314,590
• 10 Day Avg. Volume: 56,210
• 30 Day Avg. Volume: 98,136
• PEG Ratio: -1.09
• Price to Book (P/B): 3.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 143.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: ¥572.00 ▲(9.37%Upside)

Immuno-Biological Laboratories' overall score reflects strong financial performance and technical momentum, supported by a robust balance sheet and consistent revenue growth. The valuation is moderate, with potential for growth, though the stock approaches overbought technical levels.

Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model

Company Description

Immuno-Biological Laboratories Co., Ltd. (4570) is a Japanese company specialized in the development, manufacturing, and distribution of diagnostic reagents and research kits. The company primarily operates within the healthcare sector, focusing on providing products that aid in the diagnosis and research of various diseases. Their offerings include a wide range of immunological and biochemical products that cater to medical professionals and research institutions.

How the Company Makes Money

Immuno-Biological Laboratories Co., Ltd. generates revenue through the sale of its diagnostic reagents and research kits to hospitals, laboratories, and research institutions. The company's key revenue streams include direct sales to healthcare facilities and distribution agreements with partners who help market and sell their products in different regions. Additionally, the company may engage in collaborations and partnerships that enhance its product offerings or expand its market reach. Revenue is also influenced by the demand for diagnostic and research products, which can be impacted by factors such as healthcare trends, research funding, and advancements in medical science.

Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview

Summary

Immuno-Biological Laboratories exhibits a commendable financial trajectory with consistent revenue growth, improved profitability, and sound balance sheet management. The strong equity foundation and efficient operations are notable.

Income Statement

Immuno-Biological Laboratories has demonstrated strong revenue growth over the years. The gross profit margin is robust at 64.8% for 2025, indicating efficient cost management. The net profit margin improved significantly to 25.7% in 2025, showing a turnaround from losses in previous years. Both EBIT and EBITDA margins have improved, reflecting better operational efficiency.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.13 in 2025, indicating prudent leverage. A high equity ratio of 82.0% suggests strong capitalization. The return on equity stands at 16.4%, reflecting improved profitability and efficient use of equity.

Cash Flow

The operating cash flow has increased significantly, supporting positive free cash flow growth. The operating cash flow to net income ratio is 0.74, indicating strong cash generation relative to profitability. The company has shown consistent improvement in cash flow management, enhancing financial flexibility.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
948.30M	969.53M	816.70M	794.62M	647.58M	602.75M
	Gross Profit
630.76M	628.34M	517.29M	526.71M	376.70M	346.86M
	EBIT
218.54M	209.35M	104.30M	58.37M	-122.22M	-240.98M
	EBITDA
235.56M	226.55M	128.11M	-332.00M	-249.50M	-309.88M
	Net Income Common Stockholders
299.11M	249.05M	186.69M	-289.73M	-258.77M	-318.83M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
753.00M	825.73M	734.14M	614.16M	508.35M	604.19M
	Total Assets
1.70B	1.85B	1.62B	1.43B	1.71B	1.84B
	Total Debt
190.00M	204.23M	235.98M	234.99M	234.00M	90.00M
	Net Debt
-563.00M	-621.50M	-498.15M	-379.17M	-274.35M	-514.19M
	Total Liabilities
297.00M	331.03M	353.27M	355.72M	336.99M	208.76M
	Stockholders Equity
1.40B	1.51B	1.27B	1.08B	1.37B	1.63B
Cash Flow		Free Cash Flow
0.00	123.83M	115.11M	26.46M	-93.20M	-207.60M
	Operating Cash Flow
0.00	183.50M	133.78M	26.46M	-93.20M	-194.15M
	Investing Cash Flow
0.00	-53.66M	-24.50M	30.04M	-155.63M	-17.23M
	Financing Cash Flow
0.00	-31.75M	991.00K	991.00K	144.00M	-216.00M

Immuno-Biological Laboratories Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 523.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Positive. The current price of 523 is above the 20-day moving average (MA) of 518.95, above the 50-day MA of 480.80, and above the 200-day MA of 480.75, indicating a bullish trend. The MACD of 8.15 indicates Positive momentum. The RSI at 58.72 is Neutral, neither overbought nor oversold. The STOCH value of 48.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4570.

Immuno-Biological Laboratories Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	73 Outperform	¥4.87B	19.56		―	18.71%	33.40%
4884	54 Neutral	¥6.76B	―		―	12.66%	24.73%
Sector *	54 Neutral	$5.25B	3.27	-44.35%	6.27%	16.79%	-0.10%
4594	45 Neutral	¥3.92B	―		―	1473.61%	22.61%
4881	38 Underperform	¥4.66B	―		―	1056.04%	21.63%
4591	37 Underperform	¥4.02B	―		―	-96.64%	8.92%
4598	28 Underperform	¥7.34B	―		―	―	-11.46%